Cargando…
Experimentally Deduced Criteria for Detection of Clinically Relevant Fusion 3′ Oncogenes from FFPE Bulk RNA Sequencing Data
Drugs targeting receptor tyrosine kinase (RTK) oncogenic fusion proteins demonstrate impressive anti-cancer activities. The fusion presence in the cancer is the respective drug prescription biomarker, but their identification is challenging as both the breakpoint and the exact fusion partners are un...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405289/ https://www.ncbi.nlm.nih.gov/pubmed/36009413 http://dx.doi.org/10.3390/biomedicines10081866 |
_version_ | 1784773844577288192 |
---|---|
author | Rabushko, Elizaveta Sorokin, Maxim Suntsova, Maria Seryakov, Alexander P. Kuzmin, Denis V. Poddubskaya, Elena Buzdin, Anton A. |
author_facet | Rabushko, Elizaveta Sorokin, Maxim Suntsova, Maria Seryakov, Alexander P. Kuzmin, Denis V. Poddubskaya, Elena Buzdin, Anton A. |
author_sort | Rabushko, Elizaveta |
collection | PubMed |
description | Drugs targeting receptor tyrosine kinase (RTK) oncogenic fusion proteins demonstrate impressive anti-cancer activities. The fusion presence in the cancer is the respective drug prescription biomarker, but their identification is challenging as both the breakpoint and the exact fusion partners are unknown. RNAseq offers the advantage of finding both fusion parts by screening sequencing reads. Paraffin (FFPE) tissue blocks are the most common way of storing cancer biomaterials in biobanks. However, finding RTK fusions in FFPE samples is challenging as RNA fragments are short and their artifact ligation may appear in sequencing libraries. Here, we annotated RNAseq reads of 764 experimental FFPE solid cancer samples, 96 leukemia samples, and 2 cell lines, and identified 36 putative clinically relevant RTK fusions with junctions corresponding to exon borders of the fusion partners. Where possible, putative fusions were validated by RT-PCR (confirmed for 10/25 fusions tested). For the confirmed 3′RTK fusions, we observed the following distinguishing features. Both moieties were in-frame, and the tyrosine kinase domain was preserved. RTK exon coverage by RNAseq reads upstream of the junction site were lower than downstream. Finally, most of the true fusions were present by more than one RNAseq read. This provides the basis for automatic annotation of 3′RTK fusions using FFPE RNAseq profiles. |
format | Online Article Text |
id | pubmed-9405289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94052892022-08-26 Experimentally Deduced Criteria for Detection of Clinically Relevant Fusion 3′ Oncogenes from FFPE Bulk RNA Sequencing Data Rabushko, Elizaveta Sorokin, Maxim Suntsova, Maria Seryakov, Alexander P. Kuzmin, Denis V. Poddubskaya, Elena Buzdin, Anton A. Biomedicines Article Drugs targeting receptor tyrosine kinase (RTK) oncogenic fusion proteins demonstrate impressive anti-cancer activities. The fusion presence in the cancer is the respective drug prescription biomarker, but their identification is challenging as both the breakpoint and the exact fusion partners are unknown. RNAseq offers the advantage of finding both fusion parts by screening sequencing reads. Paraffin (FFPE) tissue blocks are the most common way of storing cancer biomaterials in biobanks. However, finding RTK fusions in FFPE samples is challenging as RNA fragments are short and their artifact ligation may appear in sequencing libraries. Here, we annotated RNAseq reads of 764 experimental FFPE solid cancer samples, 96 leukemia samples, and 2 cell lines, and identified 36 putative clinically relevant RTK fusions with junctions corresponding to exon borders of the fusion partners. Where possible, putative fusions were validated by RT-PCR (confirmed for 10/25 fusions tested). For the confirmed 3′RTK fusions, we observed the following distinguishing features. Both moieties were in-frame, and the tyrosine kinase domain was preserved. RTK exon coverage by RNAseq reads upstream of the junction site were lower than downstream. Finally, most of the true fusions were present by more than one RNAseq read. This provides the basis for automatic annotation of 3′RTK fusions using FFPE RNAseq profiles. MDPI 2022-08-02 /pmc/articles/PMC9405289/ /pubmed/36009413 http://dx.doi.org/10.3390/biomedicines10081866 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rabushko, Elizaveta Sorokin, Maxim Suntsova, Maria Seryakov, Alexander P. Kuzmin, Denis V. Poddubskaya, Elena Buzdin, Anton A. Experimentally Deduced Criteria for Detection of Clinically Relevant Fusion 3′ Oncogenes from FFPE Bulk RNA Sequencing Data |
title | Experimentally Deduced Criteria for Detection of Clinically Relevant Fusion 3′ Oncogenes from FFPE Bulk RNA Sequencing Data |
title_full | Experimentally Deduced Criteria for Detection of Clinically Relevant Fusion 3′ Oncogenes from FFPE Bulk RNA Sequencing Data |
title_fullStr | Experimentally Deduced Criteria for Detection of Clinically Relevant Fusion 3′ Oncogenes from FFPE Bulk RNA Sequencing Data |
title_full_unstemmed | Experimentally Deduced Criteria for Detection of Clinically Relevant Fusion 3′ Oncogenes from FFPE Bulk RNA Sequencing Data |
title_short | Experimentally Deduced Criteria for Detection of Clinically Relevant Fusion 3′ Oncogenes from FFPE Bulk RNA Sequencing Data |
title_sort | experimentally deduced criteria for detection of clinically relevant fusion 3′ oncogenes from ffpe bulk rna sequencing data |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405289/ https://www.ncbi.nlm.nih.gov/pubmed/36009413 http://dx.doi.org/10.3390/biomedicines10081866 |
work_keys_str_mv | AT rabushkoelizaveta experimentallydeducedcriteriafordetectionofclinicallyrelevantfusion3oncogenesfromffpebulkrnasequencingdata AT sorokinmaxim experimentallydeducedcriteriafordetectionofclinicallyrelevantfusion3oncogenesfromffpebulkrnasequencingdata AT suntsovamaria experimentallydeducedcriteriafordetectionofclinicallyrelevantfusion3oncogenesfromffpebulkrnasequencingdata AT seryakovalexanderp experimentallydeducedcriteriafordetectionofclinicallyrelevantfusion3oncogenesfromffpebulkrnasequencingdata AT kuzmindenisv experimentallydeducedcriteriafordetectionofclinicallyrelevantfusion3oncogenesfromffpebulkrnasequencingdata AT poddubskayaelena experimentallydeducedcriteriafordetectionofclinicallyrelevantfusion3oncogenesfromffpebulkrnasequencingdata AT buzdinantona experimentallydeducedcriteriafordetectionofclinicallyrelevantfusion3oncogenesfromffpebulkrnasequencingdata |